Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myeloblative Therapy With Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and B-Cell Malignancies
NCT00003163Phase 2Unknown
- Sponsor
- Medical College of Wisconsin
- Start
- Sep 1997
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous hematopoietic stem cells in multiple myeloma (MM) and B-cell malignancy, sponsored by Medical College of Wisconsin. Primary endpoints: Safety of myeloablative therapy with ASCT, Efficacy of myeloablative therapy with ASCT and 2 more. Status: unknown.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
multiple myeloma (MM)B-cell malignancy
Beyond the preview
Go deeper on NCT00003163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003163.